PATENT CLAIM ANALYSIS

Application Number: 15747867
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "250000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Claim (Index 12):
A method according to  claim 11 , wherein the thromboembolic disorder is selected from unstable angina, an acute coronary syndrome, atrial fibrillation, myocardial infarction, transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from medical implants, devices, or procedures in which blood is exposed to an artificial surface that promotes thrombosis.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15115314', '15747818', '15750212', '15735322', '14942013']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7859828637321078
- 35 USC 102 Novelty (BERT): 0.5933344899897623
- Combined Prediction Score: 0.7667180263578732
- Mean Citation Score: 394.471142
- Max Citation Score: 496.5713
- Similarity Product: 441.8546835720658

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test